EASL HCV Update: Rethinking Retreatment, NS5A Resistance, and Special Populations
Tuesday, June 23, 2015
1:00 PM (ET), 12:00 PM (CT), 11:00 AM (MT), 10:00 AM (PT)
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing hepatitis C virus (HCV). This webinar will review selected data from the 50th International Liver Congress focusing on data likely to have the greatest impact on the day to day treatment of persons with HCV infection. With the projected large increase in the number of patients who will require HCV treatment, clinicians who are experts in the complexities of antiretroviral management are uniquely well positioned to join our hepatology and gastroenterology colleagues in providing care for these patients, in what has become an exciting new era in HCV care.
On completion of this IAS–USA live activity, participants will be able to:
- Describe how new phase 3 trial data with sofosbuvir and simeprevir impact current treatment approaches with this regimen
- Describe the new data with grazoprevir/elbasvir in various populations
- Describe the role of interferon a in the treatment of HCV genotype 3
- Recognize new data on persistence of NS5A resistance the role it may play in determining retreatment options
- Develop an understanding of the current and future HCV treatment options for patients with end-stage renal disease
Who Should Attend
This webinar is designed for physicians who are actively treating or will be treating patients with HCV infection.
This activity is also relevant for other practitioners including nurse practitioners and other nursing professionals, physician assistants, pharmacists, and others.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday, June 22, 2015, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Education Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-15-173-L01-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Gilead Sciences, Inc
Merck & Co, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.